
Igor N Bondarenko

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5779919/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. New England Journal of Medicine, 2011, 364, 2517-2526.	27.0	4,074
2	Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 378, 113-125.	27.0	3,530
3	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, The, 2019, 393, 1819-1830.	13.7	2,347
4	Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2019, 380, 1116-1127.	27.0	2,319
5	Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC. New England Journal of Medicine, 2020, 382, 41-50.	27.0	1,725
6	The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncology, The, 2015, 16, 25-35.	10.7	1,574
7	Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. New England Journal of Medicine, 2014, 371, 1877-1888.	27.0	1,572
8	Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2009, 27, 663-671.	1.6	1,524
9	Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncology. The. 2016, 17, 425-439.	10.7	1,344
10	Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet, The, 2019, 394, 1929-1939.	13.7	1,274
11	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet, The, 2015, 386, 444-451.	13.7	1,175
12	RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer. Journal of Clinical Oncology, 2011, 29, 1252-1260.	1.6	932
13	Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study. Journal of Clinical Oncology, 2012, 30, 2046-2054.	1.6	931
14	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. New England Journal of Medicine, 2019, 381, 626-636.	27.0	909
15	Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncology, The, 2014, 15, 143-155.	10.7	823
16	Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. New England Journal of Medicine, 2018, 379, 1926-1936.	27.0	805
17	Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Annals of Oncology, 2011, 22, 1535-1546.	1.2	696
18	Weekly <i>nab</i> -Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial. Journal of Clinical Oncology, 2012, 30, 2055-2062.	1.6	676

#	Article	IF	CITATIONS
19	Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Annals of Oncology, 2013, 24, 75-83.	1.2	567
20	Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer. Journal of Clinical Oncology, 2010, 28, 4594-4600.	1.6	553
21	Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Annals of Oncology, 2017, 28, 1631-1639.	1.2	549
22	Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Annals of Oncology, 2010, 21, 1712-1717.	1.2	468
23	Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial. Journal of Clinical Oncology, 2015, 33, 1191-1196.	1.6	445
24	Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet, The, 2021, 397, 592-604.	13.7	441
25	Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet, The, 2016, 388, 2997-3005.	13.7	435
26	Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial. Journal of Clinical Oncology, 2013, 31, 3791-3799.	1.6	388
27	Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 51-65.	10.7	356
28	Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1467-1482.	10.7	265
29	Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer. Journal of Clinical Oncology, 2013, 31, 195-202.	1.6	252
30	First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study. Journal of Clinical Oncology, 2012, 30, 921-929.	1.6	244
31	Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer. JAMA Oncology, 2016, 2, 1557.	7.1	242
32	Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial. Journal of the National Cancer Institute, 2014, 106, djt337-djt337.	6.3	218
33	Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 1269-1282.	10.7	207
34	A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Annals of Oncology, 2014, 25, 1328-1333.	1.2	202
35	Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncology, The, 2011, 12, 795-805.	10.7	199
36	Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III). Journal of Clinical Oncology, 2012, 30, 3588-3595.	1.6	194

#	Article	IF	CITATIONS
37	Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Annals of Oncology, 2014, 25, 1340-1346.	1.2	187
38	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncology, The, 2018, 19, 510-520.	10.7	183
39	Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of Oncology, 2018, 29, 154-161.	1.2	161
40	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet, The, 2017, 390, 2266-2277.	13.7	153
41	Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity. Journal of Clinical Oncology, 2013, 31, 4453-4461.	1.6	147
42	Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study Journal of Clinical Oncology, 2018, 36, LBA4-LBA4.	1.6	146
43	Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Breast Cancer Research, 2016, 18, 67.	5.0	140
44	MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2018, 19, 916-929.	10.7	131
45	Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 37.	7.4	129
46	Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial. Clinical Cancer Research, 2019, 25, 4248-4254.	7.0	129
47	Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-NaÃ ⁻ ve Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 728-734.	1.1	126
48	Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial. Journal of Clinical Oncology, 2013, 31, 1341-1347.	1.6	122
49	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Annals of Oncology, 2016, 27, 417-423.	1.2	122
50	A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). Annals of Oncology, 2014, 25, 824-831.	1.2	112
51	Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. European Journal of Cancer, 2017, 70, 146-155.	2.8	108
52	Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study. Journal of Clinical Oncology, 2009, 27, 4522-4529.	1.6	97
53	Anomalous Aortic Origin of a Coronary Artery. World Journal for Pediatric & Congenital Heart Surgery, 2014, 5, 22-30.	0.8	91
54	A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). Annals of Oncology, 2015, 26, 1741-1748.	1.2	87

#	Article	IF	CITATIONS
55	Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study Journal of Clinical Oncology, 2015, 33, 4000-4000.	1.6	85
56	Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 678-689.	10.7	83
57	Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Annals of Oncology, 2012, 23, 610-617.	1.2	82
58	A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer. Gynecologic Oncology, 2017, 146, 484-490.	1.4	81
59	Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer. Journal of Clinical Oncology, 2018, 36, 968-974.	1.6	78
60	Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Annals of Oncology, 2019, 30, 766-773.	1.2	78
61	Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy. BMC Cancer, 2013, 13, 386.	2.6	75
62	Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. British Journal of Cancer, 2013, 108, 1985-1993.	6.4	74
63	Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2â^' advanced breast cancer (PALOMA-1, TRIO-18). Breast Cancer Research and Treatment, 2020, 183, 419-428.	2.5	73
64	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. European Journal of Cancer, 2015, 51, 833-840.	2.8	71
65	Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2â^' ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. Clinical Cancer Research, 2022, 28, 3433-3442.	7.0	65
66	Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor–Positive Locally Advanced or Metastatic Breast Cancer. Clinical Cancer Research, 2011, 17, 6822-6830.	7.0	63
67	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2020, 21, 105-120.	10.7	61
68	Repair of Anomalous Aortic Origin of a Coronary Artery in 113 Patients. World Journal for Pediatric & Congenital Heart Surgery, 2014, 5, 507-514.	0.8	60
69	Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. European Journal of Cancer, 2015, 51, 317-326.	2.8	58
70	Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer. Annals of Oncology, 2016, 27, 106-113.	1.2	58
71	A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results. European Journal of Cancer, 2018, 93, 19-27.	2.8	58
72	Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. Annals of Oncology, 2015, 26, 497-504.	1.2	56

#	Article	IF	CITATIONS
73	Untreated metastatic diffuse gastric adenocarcinoma (DGAC): Randomized phase III study of S-1 and cisplatin (the DIGEST trial) Journal of Clinical Oncology, 2015, 33, 4015-4015.	1.6	56
74	Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18) Journal of Clinical Oncology, 2017, 35, 1001-1001.	1.6	55
75	A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy. Journal of Clinical Oncology, 2016, 34, 1197-1207.	1.6	52
76	A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors. Current Medical Research and Opinion, 2010, 26, 2339-2346.	1.9	51
77	Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab <i>versus</i> chemotherapy plus rituximab for relapsed/refractory aggressive Bâ€cell nonâ€Hodgkin lymphoma. British Journal of Haematology, 2018, 182, 583-586.	2.5	49
78	Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study. Investigational New Drugs, 2013, 31, 1283-1293.	2.6	48
79	Long-term functional health status and exercise test variables for patients with pulmonary atresia with intact ventricular septum: AÂCongenital Heart Surgeons Society study. Journal of Thoracic and Cardiovascular Surgery, 2013, 145, 1018-1027.e3.	0.8	47
80	Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer. BMC Cancer, 2014, 14, 290.	2.6	46
81	Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensiveâ€stage small cell lung cancer: A multicentre, randomised, doubleâ€blind, placeboâ€controlled Phase <scp>II</scp> trial. International Journal of Cancer, 2021, 148, 2557-2570.	5.1	44
82	PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study. British Journal of Cancer, 2019, 120, 172-182.	6.4	43
83	A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma. Annals of Oncology, 2016, 27, 680-687.	1.2	40
84	Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase IllÂrandomized, open-label, multicenter trial Journal of Clinical Oncology, 2012, 30, 4501-4501.	1.6	40
85	Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2–positive breast cancer. European Journal of Cancer, 2019, 120, 1-9.	2.8	39
86	NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. Supportive Care in Cancer, 2017, 25, 1127-1135.	2.2	37
87	PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study. BioDrugs, 2019, 33, 555-570.	4.6	36
88	Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 845-855.	8.1	32
89	A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results. British Journal of Cancer, 2015, 113, 1140-1147.	6.4	30
90	Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study. Targeted Oncology, 2017, 12, 475-485.	3.6	30

IGOR N BONDARENKO

#	Article	IF	CITATIONS
91	A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. Annals of Oncology, 2017, 28, 2142-2148.	1.2	30
92	Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer. Annals of Oncology, 2018, 29, 1548-1553.	1.2	30
93	Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel. Lung Cancer, 2015, 90, 267-273.	2.0	26
94	Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer. Acta Oncológica, 2017, 56, 441-447.	1.8	26
95	Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation–positive melanoma receiving adjuvant vemurafenib. Annals of Oncology, 2020, 31, 153-159.	1.2	25
96	ZoptEC: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155) Journal of Clinical Oncology, 2018, 36, 5503-5503.	1.6	25
97	A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis. Clinical Cancer Research, 2016, 22, 3172-3181.	7.0	22
98	Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non–Small Cell Lung Cancer. JAMA Oncology, 2020, 6, e204429.	7.1	22
99	Phase III, Double-Blind, Controlled Trial of Atamestane Plus Toremifene Compared With Letrozole in Postmenopausal Women With Advanced Receptor-Positive Breast Cancer. Journal of Clinical Oncology, 2007, 25, 4961-4966.	1.6	21
100	Efficacy and Safety of Balugrastim Compared With Pegfilgrastim in Patients With Breast Cancer Receiving Chemotherapy. Clinical Breast Cancer, 2014, 14, 101-108.	2.4	21
101	A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel. Oncologist, 2016, 21, 7-15.	3.7	21
102	A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer. Lung Cancer, 2020, 146, 12-18.	2.0	21
103	Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial. BioDrugs, 2021, 35, 337-350.	4.6	21
104	Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor–Positive Metastatic Breast Cancer. Clinical Cancer Research, 2016, 22, 6002-6009.	7.0	20
105	Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies. Supportive Care in Cancer, 2016, 24, 267-273.	2.2	18
106	Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy. SpringerPlus, 2015, 4, 316.	1.2	17
107	Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology. Breast Cancer Research and Treatment, 2013, 138, 149-155.	2.5	16
108	A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer. Clinical Lung Cancer, 2021, 22, 531-540.	2.6	15

IGOR N BONDARENKO

#	Article	IF	CITATIONS
109	Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non–small-cell lung cancer. BMC Cancer, 2015, 15, 339.	2.6	14
110	Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane. Annals of Oncology, 2018, 29, 1195-1202.	1.2	13
111	Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC). BioDrugs, 2021, 35, 417-428.	4.6	13
112	Zolbetuximab combined with EOX as first-line therapy in advanced CLDN18.2+ gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma: Updated results from the FAST trial Journal of Clinical Oncology, 2019, 37, 16-16.	1.6	13
113	An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered inÂCombination With Pemetrexed Versus Pemetrexed Alone as Second-Line Therapy inÂPatients With Advanced Nonsquamous Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2015, 16, 92-99.	2.6	12
114	A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1) Journal of Clinical Oncology, 2013, 31, CRA8007-CRA8007.	1.6	12
115	Phase II dose-finding study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy. Medical Oncology, 2015, 32, 623.	2.5	11
116	A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer Journal of Clinical Oncology, 2017, 35, 509-509.	1.6	11
117	Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study Journal of Clinical Oncology, 2019, 37, 543-543.	1.6	11
118	Late Survival and Patient-Perceived Health Status of the Congenital Heart Surgeons' Society dextro-Transposition of the Great Arteries Cohort. Annals of Thoracic Surgery, 2019, 108, 1447-1455.	1.3	9
119	Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin Journal of Clinical Oncology, 2016, 34, LBA503-LBA503.	1.6	9
120	Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients. Supportive Care in Cancer, 2016, 24, 4913-4920.	2.2	8
121	Significant Improvements in Mortality After the Fontan Operation in Children With Down Syndrome. Annals of Thoracic Surgery, 2020, 109, 835-841.	1.3	8
122	Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study Journal of Clinical Oncology, 2021, 39, 327-327.	1.6	8
123	Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with <i>BRAF V600</i> –mutant unresectable or metastatic melanoma Journal of Clinical Oncology, 2019, 37, 9507-9507.	1.6	8
124	363â€KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1–positive, locally advanced or metastatic non–small-cell lung cancer. , 2021, 9, A390-A390.		8
125	A randomized phase 2 study of abemaciclib versus docetaxel in patients with stage IV squamous non-small cell lung cancer (sqNSCLC) previously treated with platinum-based chemotherapy Journal of Clinical Oncology, 2018, 36, 9059-9059.	1.6	7
126	Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study. BioDrugs, 2022, 36, 55-69.	4.6	7

IGOR N BONDARENKO

#	Article	IF	CITATIONS
127	Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy. BMC Cancer, 2019, 19, 122.	2.6	6
128	Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment, 2021, 188, 369-377.	2.5	6
129	Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/gefitinib (E/G) and chemotherapy: Interim subset analysis from a phase III trial Journal of Clinical Oncology, 2012, 30, 7558-7558.	1.6	6
130	Galaxy-2 trial (NCT01798485): A randomized phase 3 study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced lung adenocarcinoma Journal of Clinical Oncology, 2014, 32, TPS8118-TPS8118.	1.6	6
131	Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: Final overall survival (OS) from the phase III HERITAGE Trial Journal of Clinical Oncology, 2019, 37, 1021-1021.	1.6	6
132	Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110458.	3.2	6
133	Health-related quality of life in patients with fully resected BRAFV600 mutation–positive melanoma receiving adjuvant vemurafenib. European Journal of Cancer, 2019, 123, 155-161.	2.8	5
134	Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL) Journal of Clinical Oncology, 2014, 32, 8529-8529.	1.6	5
135	Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902) Journal of Clinical Oncology, 2015, 33, 4557-4557.	1.6	5
136	An Unusual Complication of Three-Patch Repair of Supravalvar Aortic Stenosis. Annals of Thoracic Surgery, 2014, 98, 1449-1451.	1.3	4
137	Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy Journal of Clinical Oncology, 2012, 30, 9125-9125.	1.6	4
138	Randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor–positive (ER+) metastatic breast cancer (MBC) Journal of Clinical Oncology, 2014, 32, 519-519.	1.6	4
139	Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin Journal of Clinical Oncology, 2016, 34, LBA503-LBA503.	1.6	4
140	Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: Toxicity, efficacy, and immunogenicity from the phase 3 Heritage trial Journal of Clinical Oncology, 2018, 36, 110-110.	1.6	4
141	CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane Journal of Clinical Oncology, 2019, 37, TPS1107-TPS1107.	1.6	4
142	The Phantom for Studying Foreign Bodies' Echo-Signs. International Journal of Biomedicine, 2020, 10, 124-128.	0.2	4
143	Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ≥ 50%: Results from EMPOWER-Lung 1 study Journal of Clinical Oncology, 2021, 39, 9078-9078.	1.6	3
144	Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial. Breast, 2021, 58, 18-26.	2.2	3

#	Article	IF	CITATIONS
145	A Phase II, Randomized, Multi-Centre, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 (benefilgrastim) in Women with Breast Cancer Receiving Myelotoxic Chemotherapy. Blood, 2014, 124, 1584-1584.	1.4	3
146	Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT) Journal of Clinical Oncology, 2015, 33, 610-610.	1.6	3
147	Evaluation of survival by ADCC status: Subgroup analysis of SB3 (Trastuzumab Biosimilar) and reference trastuzumab in patients with HER2-positive early breast cancer at three-year follow-up Journal of Clinical Oncology, 2019, 37, 580-580.	1.6	3
148	Outcomes of Patients With Sickle Cell Disease and Trait After Congenital Heart Disease Surgery. Annals of Thoracic Surgery, 2023, 115, 1494-1502.	1.3	3
149	Randomized, controlled, multicenter, multinational phase 2 study of docetaxel (DCT) or AXL1717 treatment in patients with squamous cell carcinoma (SCC) or adenocarcinoma (AC) of non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2014, 32, 8091-8091.	1.6	2
150	Antiangiogenic-specific adverse events (AEs) in patients with non-small cell lung cancer (NSCLC) treated with nintedanib (N) and docetaxel (D) Journal of Clinical Oncology, 2014, 32, 8100-8100.	1.6	2
151	ARIEL4: An international, multicenter randomized phase 3 study of the PARP inhibitor rucaparib vs chemotherapy in germline or somatic BRCA1- or BRCA2-mutated, relapsed, high-grade ovarian carcinoma Journal of Clinical Oncology, 2017, 35, TPS5603-TPS5603.	1.6	2
152	Hematologic adverse events following palbociclib (PAL) dose reduction in patients (pts) with hormone receptorâ€'positive (HR+)/human epidermal growth factor receptor 2â€'negative (HER2â€') advanced breast cancer (ABC): Pooled analysis from randomized phase 2 and 3 studies Journal of Clinical Oncology, 2018, 36, 1060-1060.	1.6	2
153	Milestones over the development of SB3, a trastuzumab biosimilar. Future Oncology, 2018, 14, 2795-2803.	2.4	1
154	Abstract OT1-08-09: CONTESSA: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane. , 2020, , .		1
155	A randomized phase II study of axitinib in combination with pemetrexed/cisplatin (pem/cis) as first-line therapy for nonsquamous non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2012, 30, 7551-7551.	1.6	1
156	Efficacy and safety of lipegfilgrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy Journal of Clinical Oncology, 2012, 30, e19587-e19587.	1.6	1
157	Vinflunine plus capecitabine for advanced breast cancer previously treated with or resistant to anthracycline and resistant to taxane: A phase III study versus capecitabine Journal of Clinical Oncology, 2014, 32, 1013-1013.	1.6	1
158	The effect of palbociclib (P) in combination with letrozole (L) on bone metastases in women with ER+/ HER2- metastatic breast cancer (MBC): Subanalysis from a randomized phase II study Journal of Clinical Oncology, 2015, 33, 572-572.	1.6	1
159	Results of bevacizumab biosimilar compared with RMP for the treatment of metastatic colorectal cancer Journal of Clinical Oncology, 2017, 35, e14065-e14065.	1.6	1
160	A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer Journal of Clinical Oncology, 2018, 36, 109-109.	1.6	1
161	Contessa: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC) Journal of Clinical Oncology, 2018, 36, TPS1106-TPS1106.	1.6	1
162	Additional one-year follow-up study to evaluate safety and survival in patients who have completed neoadjuvant-adjuvant treatment with SB3 (trastuzumab biosimilar) or reference trastuzumab in HER2-positive early or locally advanced breast cancer Journal of Clinical Oncology, 2018, 36, e12631-e12631.	1.6	1

#	ARTICLE	IF	CITATIONS
163	A Phase III, Randomized, Multi-Center, Open-Label, Fixed Dose, Neulasta Active-Controlled Clinical Trial of F-627, a Novel G-CSF, in Women with Breast Cancer Receiving Myelotoxic Chemotherapy. Blood, 2021, 138, 4290-4290.	1.4	1
164	Application of new methodology to allow comparison of duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial. Breast, 2011, 20, S45.	2.2	0
165	Usefulness of CT for diagnosis of breast malignancy metastasis variants to the vertebrae. Przeglad Menopauzalny, 2012, 6, 441-444.	1.3	ο
166	PO120 FACTORS AFFECTING CHANGES IN IMMUNOHISTOCHEMISTRY PHENOTYPE OF BREAST CANCER. Breast, 2013, 22, S60.	2.2	0
167	O11-5 Durvalumab(D) ± tremelimumab(T) + platinum-etoposide(EP) in 1L ES-SCLC: Characterization of long-term benefit in CASPIAN. Annals of Oncology, 2021, 32, S289.	1.2	0
168	Evaluation Of Electrocardiogram Parameters In Patients With Breast and Lung Cancer Treated With Chemotherapy and Lipegfilgrastim Or Pegfilgrastim. Blood, 2013, 122, 4856-4856.	1.4	0
169	Final analysis: Randomized, blinded, placebo-controlled phase II trial of sorafenib with and without mapatumumab in patients with advanced hepatocellular carcinoma (HCC) Journal of Clinical Oncology, 2014, 32, 4029-4029.	1.6	О
170	Evaluation of biomarker association with efficacy for abiraterone acetate (AA) plus prednisone (P) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor-positive (ER+) metastatic breast cancer (mBCa) progressing after a nonsteroidal aromatase inhibitor (NSAI) Journal of Clinical Oncology, 2014, 32, 520-520.	1.6	0
171	Abstract S5-07: A randomized, open-label, multicenter, phase 3 study of epoetin alfa (EPO) plus standard supportive care versus standard supportive care in anemic patients with metastatic breast cancer (MBC) receiving standard chemotherapy. , 2015, , .		ο
172	Efficacy and safety of adding the retinoid tamibarotene or placebo to paclitaxel/carboplatin for advanced non-small cell lung cancer Journal of Clinical Oncology, 2015, 33, e19034-e19034.	1.6	0
173	Elsiglutide in the primary prevention of chemotherapy (CT)-induced diarrhea in patients with colorectal cancer (CRC) receiving 5-fluorouracil (5-FU)-based CT: A multinational, randomized, double-blind, placebo-controlled study Journal of Clinical Oncology, 2017, 35, 10101-10101.	1.6	0
174	Plinabulin (Plin), a small molecule with anti-cancer activity and a novel mechanism of action (MoA) in docetaxel (Tax)-induced neutropenia: Phase (φ) 2 results from a head-to-head comparison with Pegfilgrastim (Peg) Journal of Clinical Oncology, 2018, 36, 2528-2528.	1.6	0
175	Abstract OT1-08-07: CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane. , 2020, , .		Ο
176	Abstract OT1-08-08: CONTESSA TRIO: A multinational, multicenter, phase 2 study of tesetaxel plus 3 different PD-(L)1 inhibitors in patients with metastatic triple-negative breast cancer (TNBC) and tesetaxel monotherapy in elderly patients with HER2- metastatic breast cancer (MBC). , 2020, , .		0
177	Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies. Cancers, 2022, 14, 1168.	3.7	0